logo
Search
  • POA Pharma Scandinavia AB and MERUS LABS INTERNATIONAL INC., expands existing Agreement.

    POA Pharma Scandinavia AB and MERUS LABS INTERNATIONAL INC., expands there existing   Promotion & Distribution Agreements for EMSELEX®/ENABLEX® with SALAGEN® for the Nordics.
     
    Toronto/Gothenburg, February 1, 2016 – Merus Labs International Inc. [TSX: MSL, NASDAQ: MSLI] is pleased to announce that through its wholly owned subsidiaries, Merus Labs B.V and Merus Labs Luxco S.à R.L., it has entered into promotion and distribution agreements with POA Pharma Scandinavia AB for the Merus Labs Salagen® product. 
     
    POA Pharma Scandinavia AB has been granted exclusive rights to distribute, Salagen® in the Nordics defined collectively as Denmark, Norway, Sweden, Finland, and Iceland.
     
    ”Salagen® with its indication, 
    Severe xerostomia following radiotherapy for cancer of the head and neck area and Symptomatic treatment of dry mouth and dry eyes in patients with Sjögren's syndrome, is a perfect fit for our competence area ENT and we are happy being able to increase our cooperation with and important, exiting and international partner,” says Tina Madsen CEO at POA.
     
    Frank Rotmann, VP & Head of European Operations: ”With our defined strategy utilizing our expertise in pharmaceutical markets in Europe and our access to capital to acquire and license specialty care branded products, it is crucial having a stable partner in the interesting Nordic market.” 
     
    Merus Labs International Inc. is a specialty pharmaceutical company engaged in the acquisition and licensing of pharmaceutical products. The Company utilizes its expertise in pharmaceutical markets and its access to capital to acquire and license niche branded products. Merus further enhances the sale and distribution of these products by the introduction of a focused marketing and promotion plan.
     
    POA Pharma Scandinavia. POA is a young Boutique Health care company, 5 years old, with offices in the four Nordic countries and in US. POA stands for Point Of Action, new ideas and new combinations and is occupied within three strategic areas:
    1. The Nordics were POA represent 14 Pharmaceutical producers from 11 countries. The products are placed in 9 areas of Competence – therapy sections.
    2. Central marketing and development of own products.
    3. Export with distribution agreement with close to 40 countries.
     
    For further information please contact:
    Merus Labs International Inc.
    Frank Rotmann, VP & Head of European Operations
    Merus Labs Luxco S.à R.L.
    Tel: + 352 27 112 7044
     
    Tina Madsen Sandström, CEO, POA Pharma Scandinavia AB
    Tel: +46 (0) 31788 05 99
     

     

    Leave a reply →